• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

极光 A 选择性抑制剂 MLN8237 抑制体外感染 HTLV-1 的 T 细胞的生长和存活。

Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro.

机构信息

Division of Molecular Virology and Oncology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.

出版信息

Cancer Sci. 2010 May;101(5):1204-11. doi: 10.1111/j.1349-7006.2010.01499.x. Epub 2010 Jan 19.

DOI:10.1111/j.1349-7006.2010.01499.x
PMID:20180813
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11158663/
Abstract

Aurora A kinase plays an essential role in the proper assembly and function of the mitotic spindle. We have shown previously that Aurora A expression is increased aberrantly in human T-cell leukemia virus type 1 (HTLV-1)-infected T-cell lines and primary adult T-cell leukemia cells, and a pan-Aurora kinase inhibitor, which inhibits both Aurora A and Aurora B kinases, reduces viability and induces apoptosis in these cells. However, the specific effects of Aurora A inhibition on HTLV-1-infected T-cells are poorly understood. In this study, we addressed this question by comparing the effects of MLN8237, a selective inhibitor of Aurora A, on cell viability, cell cycle progression, and induction of apoptosis in HTLV-1-infected and -uninfected T-cell lines. MLN8237 reduced the viability of HTLV-1-infected T-cell lines within 24 h, but its effects on that of HTLV-1-uninfected T-cell lines were moderate. MLN8237 induced early apoptosis of HTLV-1-infected T-cell lines without induction of polyploidy. It induced p53 and p21 expression in HTLV-1-infected but not in -uninfected T-cell lines, suggesting that MLN8237-treated HTLV-1-infected T-cell lines exit from mitosis and activate a p53-dependent postmitotic G(1) checkpoint, leading to G(1) arrest followed by the induction of apoptosis. Our results suggest that specific inhibition of Aurora A kinase is a potentially useful therapeutic strategy in the treatment of adult T-cell leukemia and that further in vivo exploration is warranted.

摘要

极光激酶 A 在有丝分裂纺锤体的正确组装和功能中起着至关重要的作用。我们之前已经表明,人 T 细胞白血病病毒 1(HTLV-1)感染的 T 细胞系和原代成人 T 细胞白血病细胞中异常增加了极光激酶 A 的表达,一种泛极光激酶抑制剂,它可以抑制极光 A 和极光 B 激酶,降低这些细胞的活力并诱导其凋亡。然而,极光 A 抑制对 HTLV-1 感染 T 细胞的具体影响还知之甚少。在这项研究中,我们通过比较 MLN8237(一种选择性的极光激酶 A 抑制剂)对 HTLV-1 感染和未感染的 T 细胞系的细胞活力、细胞周期进程和诱导凋亡的影响来解决这个问题。MLN8237 在 24 小时内降低了 HTLV-1 感染的 T 细胞系的活力,但对 HTLV-1 未感染的 T 细胞系的影响是适度的。MLN8237 诱导 HTLV-1 感染的 T 细胞系早期凋亡,而不诱导多倍体形成。它诱导 HTLV-1 感染的 T 细胞系而不是未感染的 T 细胞系中 p53 和 p21 的表达,这表明 MLN8237 处理的 HTLV-1 感染的 T 细胞系退出有丝分裂并激活 p53 依赖性有丝分裂后 G1 检查点,导致 G1 期阻滞,随后诱导凋亡。我们的结果表明,极光激酶 A 激酶的特异性抑制可能是治疗成人 T 细胞白血病的一种有用的治疗策略,值得进一步进行体内探索。

相似文献

1
Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro.极光 A 选择性抑制剂 MLN8237 抑制体外感染 HTLV-1 的 T 细胞的生长和存活。
Cancer Sci. 2010 May;101(5):1204-11. doi: 10.1111/j.1349-7006.2010.01499.x. Epub 2010 Jan 19.
2
Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro.极光激酶抑制剂 AZD1152 可负性影响体外 HTLV-1 感染 T 淋巴细胞的生长和存活。
Int J Cancer. 2010 Oct 1;127(7):1584-94. doi: 10.1002/ijc.25178.
3
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.新型 Aurora-A 激酶抑制剂 MLN8237 诱导多发性骨髓瘤细胞毒性和细胞周期停滞。
Blood. 2010 Jun 24;115(25):5202-13. doi: 10.1182/blood-2009-12-259523. Epub 2010 Apr 9.
4
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.在体外和体内研究中,新型 Aurora 激酶 A 抑制剂 MLN8237 可导致恶性膀胱癌细胞的存活和细胞周期进程受损。
Clin Cancer Res. 2013 Apr 1;19(7):1717-28. doi: 10.1158/1078-0432.CCR-12-2383. Epub 2013 Feb 12.
5
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.Aurora 抑制剂 MLN8237 联合多西他赛增强套细胞淋巴瘤细胞凋亡和抗肿瘤活性。
Biochem Pharmacol. 2011 Apr 1;81(7):881-90. doi: 10.1016/j.bcp.2011.01.017. Epub 2011 Feb 1.
6
Overexpression of Aurora A by loss of CHFR gene expression increases the growth and survival of HTLV-1-infected T cells through enhanced NF-kappaB activity.CHFR基因表达缺失导致的Aurora A过表达通过增强NF-κB活性增加了HTLV-1感染的T细胞的生长和存活。
Int J Cancer. 2009 Jun 1;124(11):2607-15. doi: 10.1002/ijc.24257.
7
Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.alisertib(MLN8237)是一种研究性药物,可抑制 Aurora A 和 B 的活性,抑制增殖,促进内复制,并诱导 T-NHL 细胞系凋亡,这支持其在 PTCL 治疗中的重要性。
Leuk Res. 2013 Apr;37(4):434-9. doi: 10.1016/j.leukres.2012.10.017. Epub 2012 Nov 12.
8
Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.伏瑞诺他和 MLN8237 在小儿白血病、髓母细胞瘤和神经母细胞瘤细胞系中的相加作用。
Invest New Drugs. 2013 Feb;31(1):39-45. doi: 10.1007/s10637-012-9831-9. Epub 2012 Jun 6.
9
Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.极光激酶选择性抑制剂对间变性甲状腺癌细胞系的影响。
Endocr Relat Cancer. 2014 Oct;21(5):797-811. doi: 10.1530/ERC-14-0299. Epub 2014 Jul 29.
10
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.新型 Aurora A 激酶抑制剂 MLN8237 对耐药性慢性髓性白血病有效,并显著提高了尼洛替尼的疗效。
J Cell Mol Med. 2011 Oct;15(10):2057-70. doi: 10.1111/j.1582-4934.2010.01218.x.

引用本文的文献

1
upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in rearranged lymphomas.通过极光激酶抑制实现的上调克服了重排淋巴瘤中对维奈托克的原发性耐药。
iScience. 2025 May 2;28(6):112584. doi: 10.1016/j.isci.2025.112584. eCollection 2025 Jun 20.
2
AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses.AURKA 抑制剂诱导的 PD-L1 上调会损害抗肿瘤免疫反应。
Front Immunol. 2023 Sep 12;14:1182601. doi: 10.3389/fimmu.2023.1182601. eCollection 2023.
3
The RAL Enigma: Distinct Roles of RALA and RALB in Cancer.RAL 之谜:RALA 和 RALB 在癌症中的不同作用。
Cells. 2022 May 14;11(10):1645. doi: 10.3390/cells11101645.
4
Global post-translational modification profiling of HIV-1-infected cells reveals mechanisms of host cellular pathway remodeling.对感染 HIV-1 的细胞进行的全球翻译后修饰谱分析揭示了宿主细胞途径重塑的机制。
Cell Rep. 2022 Apr 12;39(2):110690. doi: 10.1016/j.celrep.2022.110690.
5
The role of aurora A and polo-like kinases in high-risk lymphomas.极光激酶 A 和 Polo 样激酶在高危淋巴瘤中的作用。
Blood Adv. 2019 Jun 11;3(11):1778-1787. doi: 10.1182/bloodadvances.2019000232.
6
A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells.基于蛋白质组学对极光激酶A抑制剂阿利西替尼在肝癌Hep3B细胞中的抗癌活性进行的研究。
Am J Transl Res. 2017 Aug 15;9(8):3558-3572. eCollection 2017.
7
Novel immunotherapy for adult T-cell leukemia/lymphoma: Targeting aurora kinase A.成人T细胞白血病/淋巴瘤的新型免疫疗法:靶向极光激酶A。
Oncoimmunology. 2016 Oct 7;5(11):e1239006. doi: 10.1080/2162402X.2016.1239006. eCollection 2016.
8
Cucurbitacin B exerts anti-cancer activities in human multiple myeloma cells in vitro and in vivo by modulating multiple cellular pathways.葫芦素B通过调节多种细胞途径在体外和体内对人多发性骨髓瘤细胞发挥抗癌活性。
Oncotarget. 2017 Jan 24;8(4):5800-5813. doi: 10.18632/oncotarget.10584.
9
A SILAC-based proteomics elicits the molecular interactome of alisertib (MLN8237) in human erythroleukemia K562 cells.基于稳定同位素标记氨基酸的细胞培养(SILAC)的蛋白质组学揭示了阿利西尤单抗(MLN8237)在人红白血病K562细胞中的分子相互作用组。
Am J Transl Res. 2015 Nov 15;7(11):2442-61. eCollection 2015.
10
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.研究性极光激酶A抑制剂阿利西替尼(MLN8237)在东亚癌症患者中的1期研究:药代动力学及推荐的2期剂量
Invest New Drugs. 2015 Aug;33(4):942-53. doi: 10.1007/s10637-015-0258-y. Epub 2015 Jun 19.

本文引用的文献

1
Discovery and development of aurora kinase inhibitors as anticancer agents.极光激酶抑制剂作为抗癌药物的发现与开发。
J Med Chem. 2009 May 14;52(9):2629-51. doi: 10.1021/jm8012129.
2
Overexpression of Aurora A by loss of CHFR gene expression increases the growth and survival of HTLV-1-infected T cells through enhanced NF-kappaB activity.CHFR基因表达缺失导致的Aurora A过表达通过增强NF-κB活性增加了HTLV-1感染的T细胞的生长和存活。
Int J Cancer. 2009 Jun 1;124(11):2607-15. doi: 10.1002/ijc.24257.
3
ZM 447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three-dimensional culture.ZM 447439对极光激酶的抑制作用在三维培养中诱导Hep2癌细胞凋亡。
Cell Cycle. 2008 May 15;7(10):1473-9. doi: 10.4161/cc.7.10.5949. Epub 2008 Mar 12.
4
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.PHA-739358,一种有效的极光激酶抑制剂,具有与癌症相关的选择性靶点抑制特征。
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3158-68. doi: 10.1158/1535-7163.MCT-07-0444.
5
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.AZD1152是一种极光激酶B的选择性抑制剂,通过诱导凋亡来抑制人肿瘤异种移植瘤的生长。
Clin Cancer Res. 2007 Jun 15;13(12):3682-8. doi: 10.1158/1078-0432.CCR-06-2979.
6
Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation.人类嗜T淋巴细胞病毒1型(HTLV-1)的感染性与细胞转化
Nat Rev Cancer. 2007 Apr;7(4):270-80. doi: 10.1038/nrc2111.
7
Targeting aurora kinases as therapy in multiple myeloma.靶向极光激酶作为多发性骨髓瘤的治疗方法。
Blood. 2007 May 1;109(9):3915-21. doi: 10.1182/blood-2006-07-037671. Epub 2007 Jan 9.
8
Validating Aurora B as an anti-cancer drug target.验证极光激酶B作为抗癌药物靶点的有效性。
J Cell Sci. 2006 Sep 1;119(Pt 17):3664-75. doi: 10.1242/jcs.03145. Epub 2006 Aug 15.
9
The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.极光激酶抑制剂VX-680优先在p53依赖的有丝分裂后检查点功能受损的细胞中诱导核内复制和凋亡。
Cancer Res. 2006 Aug 1;66(15):7668-77. doi: 10.1158/0008-5472.CAN-05-3353.
10
PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.PHA-680632,一种具有强大抗肿瘤活性的新型极光激酶抑制剂。
Clin Cancer Res. 2006 Jul 1;12(13):4080-9. doi: 10.1158/1078-0432.CCR-05-1964.